BPC-157

Buy BPC-157 Online

Book Now

Questions about peptides? Click here to schedule a free consultation with a physician.

x
Secure Encrypted Payments

Buy BPC-157 online with a valid prescription and compare current listed pricing, available presentation details, and safety basics before checkout. You can use this page to match the selected form, strength, quantity, and handling needs to your clinician’s directions while considering US delivery from Canada. The goal is simple: help you make a careful product choice before placing an online order.

BPC-157 is a synthetic peptide, meaning a short chain of amino acids. Customers often compare peptide listings by route, total contents, vial or oral format, and storage needs. Those details matter because a listed strength, such as a total mg amount, is not the same thing as personal dosing guidance.

BPC-157 Price and Available Options

The current listed price is the starting point, but the most useful comparison is the complete selected presentation. Check whether the page shows one option or separate listings for oral BPC-157, capsules, tablets, pills, nasal spray, an injectable vial, or another format. Do not assume that names used in search results match what is available at checkout.

For BPC-157 price comparisons, review the strength or total peptide content, quantity, pack count, and any required handling note together. A BPC-157 5mg vial and a BPC-157 10mg vial, for example, would represent different total contents if both were displayed; they should not be compared as the same order. Oral forms may list units differently from injectable products, so check the product selector before comparing cost.

If you are paying without insurance, compare the cash-pay total against the selected quantity and any handling needs shown during checkout. A lower-looking unit amount may not reflect the same total contents, route, or pack size. The practical decision is not only what appears cheapest at first glance, but what accurately matches the ordered presentation.

Quick tip: Compare the selected listing, quantity, and total contents before you compare the final checkout total.

Item to compareWhy it affects the order
PresentationOral, nasal, injectable, or vial formats may be listed separately and handled differently.
Strength or contentsmg amounts may describe total product contents, not a personal dose.
Quantity or pack countMore units can change the total supply even when the product name is similar.
Handling notesTemperature, light, or storage directions can affect travel and receipt planning.
Checkout detailsCash-pay, shipping, and required order fields can affect the final path.

How to Order Online

When you are ready to buy BPC-157 online, begin with the presentation that matches your clinician’s directions. Add the selected product to checkout only after the form, strength, and quantity align with the written order. If the listing does not match those details, pause and ask the prescriber or support team to clarify before completing the order.

During checkout, you may need to provide prescriber information or supporting documents. If needed, prescription details may be checked with your prescriber before dispensing. This helps prevent form or strength mismatches, especially when peptide products are searched under several names.

Cash-pay ordering may be helpful when insurance is not used, but it is still tied to the selected product and safety review. Available checkout fields can also show shipping choices; if express shipping is offered, do not use faster logistics as a reason to skip product checks.

Why a Structured Peptide Order Path Matters

Peptide searches can lead to research-use listings, wellness products, and supplement-style pages. A structured prescription order path keeps the selected product tied to a prescriber’s directions rather than reviews, celebrity routines, or unverified before-and-after claims.

That matters for this product because public interest in benefits is ahead of strong human evidence. In U.S. consumer wellness channels, BPC-157 has been flagged as an unapproved drug and not a dietary ingredient, so avoid products promoted as ordinary supplements. If your clinician has written for a peptide product, compare what is listed here against that plan.

BorderFreeHealth supports cash-pay prescription orders when applicable. That can be useful for patients comparing access outside standard insurance billing, but it does not change the need to match the listed item to clinician direction and safety checks.

Forms, Strengths, and Dose Details to Match

Form is one of the most important product decisions. Oral BPC-157, BPC-157 capsules, tablets, and pills may be described differently from injectable or nasal products. If a BPC-157 injection or injectable vial is shown, review whether the listing describes total vial contents, concentration, or supplied quantity. The words vial, 5mg, and 10mg usually refer to product contents, not a personal dose.

Do not substitute one route for another because the route can change handling, administration steps, and monitoring. A nasal spray, capsule, tablet, or vial may involve different storage and supplies. Use the product page to confirm what is included in the order and what is not shown, such as administration supplies or reconstitution items.

Why it matters: Matching the listed presentation prevents a route or strength mismatch at checkout.

  • Form: Check whether the product is oral, nasal, injectable, or another listed presentation.
  • Strength: Match the mg amount or concentration to the written order.
  • Quantity: Compare units, vials, tablets, capsules, or sprays as displayed.
  • Supplies: Do not assume needles, syringes, or mixing items are included.
  • Directions: Follow clinician instructions, not online dose examples.

What This Peptide Is Used For

BPC-157 is a laboratory-made pentadecapeptide, meaning a 15-amino-acid peptide, related to a protein fragment found in gastric juice. It is discussed in research settings for tissue repair, tendon or ligament models, inflammation, and gastrointestinal protection. Most supportive evidence comes from animal or laboratory studies, so human benefits are not established in the way they are for approved medicines.

On a product page, that uncertainty changes how you should evaluate the listing. The product should be selected because it matches a clinician-directed plan, not because another person reported a result online. If you are comparing treatment areas, the Ligament Healing Product List and Inflammation Product List can help you browse related product categories without replacing clinical guidance.

It is not a growth hormone. It also is not an everyday dietary supplement. Athletes and military-affiliated users should be especially careful because some peptide products may be prohibited under sport or occupational rules.

Storage, Handling, and Travel Checks

Storage instructions should come from the package label and the dispensed presentation. Peptides may be sensitive to heat, light, mixing, or contamination, particularly when supplied as an injectable vial. If the page or package gives temperature directions, follow those instructions and avoid leaving the product in a vehicle, gym bag, or checked luggage.

If an injectable presentation is selected, handling details become part of the purchase decision. Review whether the vial is sealed, whether the product is supplied as a powder or solution, and whether additional supplies are listed separately. Do not use a product that appears damaged, contaminated, or different from the expected presentation.

Travel can add practical issues. Keep the product in its original packaging when possible, carry relevant treatment information with travel documents, and plan for storage before leaving home. Cross-border deliveries may require extra attention to address details, package receipt, and temperature exposure after arrival.

Safety Risks and When to Pause Ordering

Safety information for this peptide is less complete than for many approved medications. Reported or plausible issues may include nausea, headache, dizziness, flushing, fatigue, appetite changes, or local irritation with injections. Because human data are limited, mild symptoms should not be used to assume long-term safety.

Pause ordering and speak with a clinician before use if you are pregnant, trying to become pregnant, breastfeeding, have a history of cancer, have immune system problems, or have significant kidney, liver, heart, or bleeding conditions. Also ask first if you are recovering from surgery, managing an active infection, or using medicines that affect clotting or immune response.

Seek urgent medical help for signs of an allergic reaction, chest pain, trouble breathing, swelling of the lips or throat, fainting, severe abdominal pain, or signs of infection around an injection site. These symptoms are not routine product-selection issues; they need prompt clinical attention.

Because BPC-157 products may be promoted aggressively online, avoid making safety decisions from reviews or before-and-after images. A product listing cannot tell whether this peptide is appropriate for your medical history.

Interactions, Monitoring, and Clinician Questions

Interaction data are limited, which makes a complete medication list important. Include prescription medicines, over-the-counter products, supplements, hormones, anticoagulants, immunosuppressants, and other peptide products when you speak with your clinician. Mention recent injections, procedures, injuries, or active skin problems if an injectable route is being considered.

Monitoring may focus on the reason the peptide was prescribed, changes in symptoms, side effects, and whether any lab work is appropriate. People with kidney or liver disease should ask whether extra monitoring is needed because formal safety data in these groups are limited. Do not change dose, route, or duration based on product availability.

Helpful questions include which presentation should be used, what strength or total contents should appear on the label, how it should be stored, what side effects should stop use, and when follow-up should occur. Write the answers down before comparing listings so the order is easier to match.

Compare Related Options

Peptide products are not interchangeable. GHK-CU, collagen-support supplements, anti-inflammatory medicines, and other options can have different purposes, formulations, evidence standards, and safety issues. If your clinician discusses another peptide, compare the ingredient, route, and monitoring plan rather than assuming it works like the selected product.

For a nearby product comparison, GHK-CU is a separate peptide listing with its own product details. Use that comparison only to understand differences in ingredient and presentation; it should not be used to substitute products without clinician direction.

Authoritative Sources

The following sources are included because they address evidence quality, safety uncertainty, or regulatory concerns that matter before ordering a peptide product.

This content is for informational purposes only and is not a substitute for professional medical advice.

Express Shipping - from $25.00

Shipping with this method takes 3-5 days

Prices:
  • Dry-Packed Products $25.00
  • Cold-Packed Products $35.00
Shipping Countries:
  • United States (all contiguous states**)
  • Worldwide (excludes some countries***)

Standard Shipping - $15.00

Shipping with this method takes 5-10 days

Prices:
  • Dry-Packed Products $15.00
  • Not available for Cold-Packed products
Shipping Countries:
  • United States (all contiguous states**)
  • Worldwide (excludes some countries***)

Rewards Program

Earn points on birthdays, product orders, reviews, friend referrals, and more! Enjoy your medication at unparalleled discounts while reaping rewards for every step you take with us.

You can read more about rewards here.

POINT VALUE

100 points
1 USD

How to earn points

  • 1Register and/or Login
    Create an account and start earning.
  • 2Earn Rewards
    Earn points every time you shop or perform certain actions.
  • 3Redeem
    Redeem points for exclusive discounts.

You Might Also Like

Epithalon

$47.49

  • In Stock
  • Express Shipping
Our Price $47.49
Select options This product has multiple variants. The options may be chosen on the product page
TB500

$61.74

  • In Stock
  • Express Shipping
Our Price $61.74
Select options This product has multiple variants. The options may be chosen on the product page
Ipamorelin

$47.49

  • In Stock
  • Express Shipping
Our Price $47.49
Select options This product has multiple variants. The options may be chosen on the product page
Retatrutide

$85.49

  • In Stock
  • Express Shipping
Our Price $85.49
Select options This product has multiple variants. The options may be chosen on the product page

Peptide Screening Form

Patient Information

Please provide your basic demographic information.

Type your date of birth in MM/DD/YYYY format.

Peptides of Interest

Peptides of Interest

Select the peptides you are interested in or have been recommended.

Medical History & Screening

Medical History & Screening

Please indicate if any of the following apply to you. Red flag alerts will appear if a condition contraindicates any of the available peptide therapies.

Contraindicated for CJC-1295: Growth hormone-releasing peptides like CJC-1295 are contraindicated in patients with active cancer because they may promote cell proliferation and tumor growth.

Contraindicated for Ipamorelin: Ipamorelin stimulates growth hormone release, which may promote tumor growth and cell proliferation in active cancers.

Contraindicated for Sermorelin: Sermorelin increases growth hormone production, which may stimulate growth of existing tumors.

Contraindicated for BPC-157: BPC-157 promotes angiogenesis (new blood vessel formation), which could support tumor growth and metastasis in active cancers.

Contraindicated for AOD-9604: Although AOD-9604 is a modified GH fragment, it may still interact with growth-related pathways in patients with active malignancies.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 promotes cell migration and angiogenesis, which may facilitate tumor growth and metastasis in active cancers.

Contraindicated for GHK-Cu: GHK-Cu promotes angiogenesis and tissue remodeling, which may support tumor growth in patients with active cancer.

Contraindicated for Epithalon (Epitalon): Epithalon stimulates telomerase activity. Cancer cells exploit telomerase to achieve immortality, potentially accelerating tumor growth.

Contraindicated for Semax: Semax has neurotrophic properties that promote cell growth, which may be concerning in patients with active malignancies.

Contraindicated for MOTS-c: MOTS-c influences cellular metabolism and AMPK pathways. Effects on cancer cell metabolism are not fully understood.

Contraindicated for Tesamorelin: Tesamorelin stimulates growth hormone release, which may promote tumor growth in patients with active malignancies.

Contraindicated for Hexarelin: Hexarelin stimulates growth hormone release, which may promote tumor growth and cell proliferation.

Contraindicated for GHRP-6: GHRP-6 stimulates growth hormone release, which may promote tumor growth in active cancers.

Contraindicated for GHRP-2: GHRP-2 stimulates growth hormone release, which may promote tumor growth in active malignancies.

Contraindicated for Melanotan II: Melanotan II stimulates melanocyte activity. In patients with skin cancers, particularly melanoma, it may accelerate disease progression.

Contraindicated for Dihexa: Dihexa activates hepatocyte growth factor (HGF) pathways, which can promote tumor growth and metastasis.

Contraindicated for Kisspeptin-10: Kisspeptin-10 influences reproductive hormone pathways. Hormone-sensitive cancers may be affected by altered GnRH and gonadotropin levels.

Contraindicated for Humanin: Humanin has anti-apoptotic properties that may protect cancer cells from programmed cell death, potentially supporting tumor survival.

Contraindicated for Retatrutide: Retatrutide acts on multiple metabolic pathways including GLP-1 and GIP receptors. Its effects on cell proliferation in patients with active malignancies have not been fully characterized.

Contraindicated for CJC-1295: CJC-1295 stimulates growth hormone release, which can increase IGF-1 levels. Elevated IGF-1 has been associated with cancer recurrence.

Contraindicated for Ipamorelin: The growth hormone and IGF-1 elevation from Ipamorelin may increase the risk of cancer recurrence.

Contraindicated for Sermorelin: Growth hormone stimulation from Sermorelin elevates IGF-1, which has been linked to increased cancer recurrence risk.

Contraindicated for BPC-157: The pro-angiogenic properties of BPC-157 may potentially support recurrence by promoting blood vessel growth that could feed dormant cancer cells.

Contraindicated for TB-500 (Thymosin Beta-4): The pro-angiogenic and cell-migration properties of TB-500 may increase the risk of cancer recurrence.

Contraindicated for Epithalon (Epitalon): Telomerase activation from Epithalon may increase the risk of cancer recurrence by supporting abnormal cell survival.

Contraindicated for Tesamorelin: Growth hormone and IGF-1 elevation from Tesamorelin may increase risk of cancer recurrence.

Contraindicated for Hexarelin: Elevated growth hormone and IGF-1 from Hexarelin may increase risk of cancer recurrence.

Contraindicated for GHRP-6: Growth hormone and IGF-1 elevation from GHRP-6 may increase risk of cancer recurrence.

Contraindicated for GHRP-2: Elevated IGF-1 from GHRP-2-stimulated growth hormone may increase cancer recurrence risk.

Contraindicated for Melanotan II: Melanocortin stimulation from Melanotan II may increase melanoma recurrence risk in patients with skin cancer history.

Contraindicated for Dihexa: HGF pathway activation from Dihexa may increase cancer recurrence risk through pro-growth signaling.

Contraindicated for Humanin: The cytoprotective effects of Humanin may increase cancer recurrence risk by inhibiting apoptosis in dormant cancer cells.

Contraindicated for Retatrutide: GLP-1 receptor agonists have been linked to thyroid C-cell tumors in animal studies. Retatrutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

Contraindicated for Retatrutide: Retatrutide is contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) due to the risk of medullary thyroid carcinoma associated with GLP-1 receptor agonists.

Contraindicated for CJC-1295: CJC-1295 has not been studied in pregnancy and may affect fetal development through altered growth hormone levels.

Contraindicated for Ipamorelin: Ipamorelin has not been studied in pregnancy. Altered growth hormone levels may impact fetal development.

Contraindicated for Sermorelin: Sermorelin is not approved for use during pregnancy due to potential effects on fetal growth and development.

Contraindicated for BPC-157: BPC-157 has not been adequately studied in human pregnancy. Its tissue-modulating effects may pose risks to fetal development.

Contraindicated for Thymosin Alpha-1: Immune modulation during pregnancy may disrupt the delicate immune tolerance required for fetal development.

Contraindicated for PT-141: PT-141 is contraindicated in pregnancy as melanocortin receptor activation may affect fetal development.

Contraindicated for AOD-9604: AOD-9604 has not been studied in pregnancy. Its effects on fetal metabolism are unknown.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 has not been studied in pregnancy. Its tissue-remodeling effects may pose risks to fetal development.

Contraindicated for GHK-Cu: GHK-Cu has not been studied in pregnancy. Copper peptide effects on fetal development are unknown.

Contraindicated for Epithalon (Epitalon): Epithalon has not been studied in pregnancy. Effects on fetal cellular development are unknown.

Contraindicated for Selank: Selank has not been studied in pregnancy. Its neuroactive effects may impact fetal brain development.

Contraindicated for Semax: Semax has not been studied in pregnancy. Its neuroactive and hormonal effects may affect fetal development.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): DSIP has not been studied in pregnancy. Its neuroendocrine effects may impact fetal development.

Contraindicated for MOTS-c: MOTS-c has not been studied in pregnancy. Its metabolic effects may impact fetal development.

Contraindicated for Tesamorelin: Tesamorelin is contraindicated in pregnancy due to potential effects on fetal growth from altered growth hormone levels.

Contraindicated for Hexarelin: Hexarelin has not been studied in pregnancy. Altered growth hormone levels may impact fetal development.

Contraindicated for GHRP-6: GHRP-6 has not been studied in pregnancy. Growth hormone modulation may affect fetal development.

Contraindicated for GHRP-2: GHRP-2 has not been studied in pregnancy. Its effects on fetal growth and development are unknown.

Contraindicated for Melanotan II: Melanotan II is contraindicated in pregnancy due to unknown effects on fetal development from melanocortin receptor activation.

Contraindicated for LL-37: LL-37 has not been studied in pregnancy. Immune modulation may disrupt maternal-fetal immune tolerance.

Contraindicated for KPV: KPV has not been studied in pregnancy. Its immunomodulatory effects may impact fetal development.

Contraindicated for Dihexa: Dihexa has not been studied in pregnancy. Its neurotrophic and growth factor effects may impact fetal development.

Contraindicated for 5-Amino-1MQ: 5-Amino-1MQ has not been studied in pregnancy. Its metabolic enzyme inhibition may affect fetal development.

Contraindicated for SS-31 (Elamipretide): SS-31 has not been studied in pregnancy. Its effects on mitochondrial function in developing tissues are unknown.

Contraindicated for PE-22-28: PE-22-28 has not been studied in pregnancy. Its neurogenic effects may impact fetal brain development.

Contraindicated for Kisspeptin-10: Kisspeptin-10 directly affects reproductive hormones and GnRH signaling. Use during pregnancy may disrupt hormonal balance critical for fetal development.

Contraindicated for Humanin: Humanin has not been studied in pregnancy. Its effects on fetal cellular development and apoptosis pathways are unknown.

Contraindicated for KLOW: KLOW has not been studied in pregnancy. Effects on fetal development are unknown.

Contraindicated for GLOW: GLOW has not been studied in pregnancy. Effects on fetal development are unknown.

Contraindicated for Retatrutide: Retatrutide has not been studied in pregnancy. GLP-1 receptor agonists may affect fetal development and maternal glucose regulation.

Contraindicated for CJC-1295: Safety of CJC-1295 during breastfeeding has not been established. Growth hormone modulation could affect lactation.

Contraindicated for BPC-157: Insufficient safety data exists for BPC-157 use during breastfeeding.

Contraindicated for PT-141: Safety of PT-141 during breastfeeding has not been established.

Contraindicated for AOD-9604: Insufficient safety data for AOD-9604 during breastfeeding.

Contraindicated for Selank: Safety of Selank during breastfeeding has not been established. Neuroactive peptides may pass into breast milk.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): Safety of DSIP during breastfeeding has not been established.

Contraindicated for KPV: Safety of KPV during breastfeeding has not been established.

Contraindicated for 5-Amino-1MQ: Safety of 5-Amino-1MQ during breastfeeding has not been established.

Contraindicated for PE-22-28: Safety of PE-22-28 during breastfeeding has not been established. Neuroactive peptides may pass into breast milk.

Contraindicated for Kisspeptin-10: Kisspeptin-10 modulates reproductive hormones, which may affect lactation and hormonal balance during breastfeeding.

Contraindicated for KLOW: Safety of KLOW during breastfeeding has not been established.

Contraindicated for GLOW: Safety of GLOW during breastfeeding has not been established.

Contraindicated for Retatrutide: Safety of Retatrutide during breastfeeding has not been established. It is unknown whether the peptide is excreted in breast milk.

Contraindicated for CJC-1295: Growth hormone elevation from CJC-1295 can worsen diabetic retinopathy by promoting abnormal blood vessel growth in the retina.

Contraindicated for Ipamorelin: Elevated growth hormone from Ipamorelin can accelerate retinal neovascularization in diabetic retinopathy.

Contraindicated for GHRP-6: Elevated growth hormone from GHRP-6 can worsen diabetic retinopathy by promoting abnormal blood vessel growth.

Contraindicated for GHRP-2: Growth hormone elevation from GHRP-2 can accelerate retinal neovascularization in diabetic retinopathy.

Contraindicated for Retatrutide: Rapid improvement in glycemic control from Retatrutide may temporarily worsen diabetic retinopathy. Close ophthalmologic monitoring is recommended.

Contraindicated for CJC-1295: Growth hormone-releasing peptides can elevate intracranial pressure, worsening existing intracranial hypertension.

Contraindicated for Sermorelin: Growth hormone elevation from Sermorelin can increase intracranial pressure.

Contraindicated for Tesamorelin: Growth hormone elevation from Tesamorelin can increase intracranial pressure.

Contraindicated for CJC-1295: CJC-1295 acts on the pituitary gland. Existing pituitary disorders may lead to unpredictable or dangerous hormone responses.

Contraindicated for Ipamorelin: Ipamorelin directly stimulates the pituitary gland. Pre-existing pituitary conditions may result in adverse hormonal responses.

Contraindicated for Sermorelin: Sermorelin requires a functioning pituitary gland. Pituitary disorders may prevent proper response or cause adverse effects.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): DSIP affects neuroendocrine signaling involving the pituitary gland. Pre-existing pituitary conditions may lead to unpredictable effects.

Contraindicated for Tesamorelin: Tesamorelin acts directly on the pituitary gland. Pre-existing pituitary disorders may cause unpredictable hormonal responses.

Contraindicated for Hexarelin: Hexarelin acts on the pituitary gland. Pre-existing pituitary conditions may result in adverse hormonal responses.

Contraindicated for GHRP-6: GHRP-6 acts directly on the pituitary gland. Pre-existing disorders may cause adverse hormonal effects.

Contraindicated for GHRP-2: GHRP-2 directly stimulates the pituitary gland. Pre-existing pituitary disorders may cause unpredictable responses.

Contraindicated for Kisspeptin-10: Kisspeptin-10 stimulates the hypothalamic-pituitary axis. Pre-existing pituitary disorders may lead to unpredictable hormonal responses.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 stimulates T-cell activity and immune response. In patients with autoimmune conditions, this can trigger disease flares.

Contraindicated for Epithalon (Epitalon): Epithalon may modulate immune function through its effects on the pineal gland, potentially exacerbating autoimmune conditions.

Contraindicated for Melanotan II: Melanotan II modulates immune function through melanocortin receptors, potentially exacerbating autoimmune conditions.

Contraindicated for LL-37: LL-37 is a potent immune activator. In autoimmune conditions, it may trigger inflammatory flares and worsen disease activity.

Contraindicated for KLOW: Peptide blends may modulate immune function. Patients with autoimmune conditions should consult their provider before use.

Contraindicated for GLOW: Peptide blends may modulate immune function. Patients with autoimmune conditions should consult their provider before use.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 enhances immune function, which directly counteracts immunosuppressive therapy required to prevent organ rejection.

Contraindicated for LL-37: LL-37 enhances immune function, which may counteract immunosuppressive therapy in transplant recipients.

Contraindicated for PT-141: PT-141 affects blood pressure and cardiovascular function. Patients with heart disease face increased risk of adverse cardiac events.

Contraindicated for Hexarelin: Hexarelin has been shown to affect cardiac function and cortisol release. Patients with cardiovascular disease should use caution.

Contraindicated for Melanotan II: Melanotan II affects cardiovascular function and can cause nausea and flushing. Heart disease patients should avoid use.

Contraindicated for PT-141: PT-141 can cause transient increases in blood pressure. Uncontrolled hypertension increases the risk of cardiovascular events.

Contraindicated for Semax: Semax can influence blood pressure regulation. Patients with uncontrolled hypertension should use caution.

Contraindicated for Melanotan II: Melanotan II can cause blood pressure fluctuations. Patients with uncontrolled hypertension face increased cardiovascular risk.

Contraindicated for Dihexa: Dihexa may influence cardiovascular function. Patients with uncontrolled hypertension should exercise caution.

Contraindicated for AOD-9604: Patients with severe kidney disease may have impaired clearance of AOD-9604 metabolites.

Contraindicated for MOTS-c: Patients with severe kidney disease may have impaired clearance of MOTS-c metabolites.

Contraindicated for 5-Amino-1MQ: Patients with kidney disease may have impaired clearance of 5-Amino-1MQ metabolites.

Contraindicated for SS-31 (Elamipretide): Patients with severe kidney disease may have impaired clearance of SS-31 and its metabolites.

Contraindicated for Retatrutide: Patients with severe kidney disease may have impaired clearance of Retatrutide. Dose adjustment or avoidance may be necessary.

Contraindicated for GHK-Cu: Copper metabolism is heavily dependent on liver function. Patients with liver disease may accumulate copper to toxic levels.

Contraindicated for 5-Amino-1MQ: 5-Amino-1MQ affects metabolic enzyme pathways. Patients with liver disease may experience altered drug metabolism and increased toxicity risk.

Contraindicated for Retatrutide: Retatrutide is metabolized hepatically. Patients with significant liver impairment may experience altered drug levels and increased risk of adverse effects.

Contraindicated for Retatrutide: GLP-1 receptor agonists, including Retatrutide, have been associated with an increased risk of pancreatitis. Patients with a history of pancreatitis should avoid use.

Contraindicated for BPC-157: BPC-157 affects the nitric oxide system and may influence blood clotting. Patients with clotting disorders should avoid use.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 can influence blood clotting pathways. Patients with clotting disorders or on anticoagulants should avoid use.

Contraindicated for Selank: Selank is derived from tuftsin, which can influence immune and coagulation pathways. Patients with clotting disorders should use caution.

Contraindicated for SS-31 (Elamipretide): SS-31 has been associated with injection site reactions. Patients with known peptide allergies should be monitored.

Contraindicated for KLOW: Multi-component peptide blends carry increased risk of allergic reactions. Patients with known peptide allergies should be monitored.

Contraindicated for GLOW: Multi-component peptide blends carry increased risk of allergic reactions. Patients with known peptide allergies should be monitored.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 directly opposes immunosuppressive medications, potentially causing dangerous drug interactions.

Contraindicated for LL-37: LL-37 stimulates immune responses, potentially opposing immunosuppressive medications.

Contraindicated for KPV: KPV has anti-inflammatory and immune-modulating effects that may interact with immunosuppressive medications.

Current Medications

List all medications, supplements, and treatments you are currently using.

Additional Notes

Medical Disclaimer

This screening questionnaire is for informational and pre-consultation purposes only. It does not constitute medical advice, diagnosis, or a treatment recommendation.

All peptide therapy protocols must be prescribed and supervised by a licensed healthcare provider. The contraindication information provided here is based on general clinical guidelines and may not reflect every individual’s unique medical circumstances.

Peptide therapies are used off-label in many cases. Results vary by individual. Borderfreehealth.com does not guarantee outcomes from any peptide therapy program.

By submitting this form, you acknowledge that a qualified medical professional will review your responses and determine appropriate treatment options. Do not discontinue any current medications or begin any new treatment based solely on the results of this screening.